Latest Regulatory News

ALS Limited reported a 16% revenue increase to nearly $3 billion in FY2025, driven by acquisitions and organic growth, while underlying net profit after tax dipped slightly. The company announced a $350 million equity raise to fund expansion and sustainability initiatives.

Vulcan Energy has begun drilling the first new well for its Phase One Lionheart Project in Germany, marking a critical step toward expanding its renewable geothermal energy and lithium production capacity.

Future Battery Minerals Ltd has identified significant gold mineralisation at its Miriam Project in Western Australia, setting the stage for a targeted drilling campaign in July 2025. The company’s review of historical data highlights multiple high-potential prospects, including the Forrest zone with continuous gold intercepts over 600 metres.

RPMGlobal Holdings has announced a 12-month extension to its on-market share buy-back program, adding up to 11 million shares to be repurchased. This move underscores the company’s confidence in its valuation and capital management strategy.

Metro Performance Glass reported a net loss for FY25 amid market softness but outlines a clear recovery plan with leadership changes and an equity raise to strengthen its position.

Cauldron Energy Limited has announced a fully underwritten entitlement offer to raise nearly $2 million, aimed at advancing its Yanrey Uranium Project and shoring up working capital. The offer, priced at $0.006 per share, could reshape shareholder control dynamics depending on participation.

Cauldron Energy has launched a fully underwritten entitlement offer to raise nearly $2 million, aiming to advance its Yanrey Uranium Project amid growing global uranium demand and hopes for regulatory change in Western Australia.

Turners Automotive Group has updated its dividend details for the quarter ending March 2025, declaring a fully franked ordinary dividend alongside a supplementary unfranked payout and a Dividend Reinvestment Plan with a 2% discount.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

OncoSil Medical has launched a $8.7 million capital raising via a Share Purchase Plan and Placement, seeking shareholder approval for options issuance and a 400:1 share consolidation.

OncoSil Medical has secured $8.7 million through a placement and share purchase plan to fund commercialization of its pancreatic cancer treatment device, aiming for positive cash flow by mid-2026. Near-completion clinical trials could soon unlock broader market access.

Axel REE Limited has responded to ASX Compliance queries confirming the timely disclosure of its latest rare earth element drilling results at the Poços de Caldas Caldera, emphasizing the incremental nature of the findings and ongoing compliance with listing rules.